Skip to main content
. 2010 May 28;67(3):657–666. doi: 10.1007/s00280-010-1326-9

Fig. 2.

Fig. 2

Relationship between peginterferon α-2b area under the concentration–time curve during the dosing interval (AUCtau) and absolute neutrophil count (ANC) changes as a percentage of baseline in patients with melanoma (n = 32) and solid tumors (n = 34) receiving various doses of peginterferon α-2b (3–12 patients in each dose group)